Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of JS212 in advanced malignant solid tumors
CTR20251056Phase 2Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JS212 in Nonhematologic neoplasms, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2025; status: active.
02
Drugs
JS212
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251056.